Trillium Therapeutics Cash Flow - Quarterly (NASDAQ:TRIL)

Add to My Stocks
$6.1 $0.2 (3.17%) TRIL stock closing price Sep 19, 2018 (Closing)

The Trillium Therapeutics cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. This statement shows details about the cash generated and spent during a particular quarter, while the other two statements give details about Trillium Therapeutics profits and Trillium Therapeutics debt. Items like capital purchases, bank loan payments etc. which have a direct impact on the cash position of a company come out through the statemement of cash flows and help an investor who undertakes the Trillium Therapeutics stock analysis. Trillium Therapeutics generated $-15.48M cash from operating activities in till this quarter of 2018 Q2. Trillium Therapeutics had an outflow of $-15.48M from operating activities, $-0.04M spend due to financing activities, and $11.16M inflow due to investing activities till 2018 Q2.

View and download details of Trillium Therapeutics cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow1.22M-3.63M2.79M1.73M-3.23M2.39M1.52M-
Net Increase (Decrease) in Assets Liabilities-1.25M-0.54M5.74M2.88M1.75M-2.31M1.32M--0.26M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net--0.82M4.54M5.47M3.18M-1.15M1.24M1.3M-
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.04M-0.01M-0.36M-0.08M-0.06M-0.01M-2.24M-2.1M-2.03M-1.3M
Acquisition Disposition of Subsidiaires-------7.23M-7.34M-7.43M-6.98M
Increase (Decrease) in Investments11.21M7.95M-43.96M-31.16M-26.96M-9.52M----
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares--48.37M31.11M28.99M-----
Issuance (Repayment) of Debt Securities-0.04M-0.02M-0.09M-0.07M-0.04M-0.02M-0.07M-0.11M-0.04M-0.02M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash---0.14M-1.29M-0.97M-0.23M-0.94M-2.03M-2.92M-2.63M
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year21.98M38.93M65.52M20.5M29.4M1.33M2.69M---
Cash & Equivalents at Year End18.31M23.27M21.87M22.44M27.99M21.71M38.11M42.61M46.61M48M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

While Trillium Therapeutics stock price history provides the price history of a stock, Trillium Therapeutics stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:

  • Net Change in Cash and Cash Equivalents: A positive net change in cash and cash equivalents shows that Trillium Therapeutics is able to meet its expenditure and grow cash at hand which demonstrates the financial strength of the company's balance sheet. Also see - Trillium Therapeutics stock price movement.
  • Trillium Therapeutics decreased its cash from operating activities to $-15.48M till 2018 Q2. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash from investing stood at a positive value of $11.16M for TRIL stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $-0.04M for Trillium Therapeutics.

Key Financial Ratios For Trillium Therapeutics Cash Flow